Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V C Jordan

Showing results (121-130 of 365) with videos related to

Pageof 37
Sort By:
British Journal of Pharmacology|November 1, 1978
Contrasting subcellular responses to monohydroxytamoxifen and oestradiol benzoate in the immature rat uterus [proceedings]C J Dix, V C Jordan
Biochemical Pharmacology|January 15, 1983
Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapyR R Bain, V C Jordan
Journal of Mammary Gland Biology and Neoplasia|March 8, 2000
The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogensD A Tonetti, V C Jordan
Oncology (Williston Park, N.Y.)|February 1, 1997
Risks and benefits of tamoxifen therapyV J Assikis, V C Jordan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Clinical potential of new antiestrogensW J Gradishar, V C Jordan
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1996
Tamoxifen and endometrial cancer: from experiment to patientV J Assikis, V C Jordan
Cancer Letters|May 25, 1995
Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogueW H Catherino, V C Jordan
Life Sciences|January 1, 1988
Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the ratP M Ravdin, V C Jordan
British Journal of Clinical Pharmacology|April 1, 1979
Control of experimental breast cancer by antioestrogenic therapies [proceedings]C J Dix, V C Jordan
Gynecologic Oncology|May 1, 1992
Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancerD M Wolf, V C Jordan
Pageof 37

Showing results (121-130 of 365) with videos related to

Sort By:
Pageof 37
British Journal of Pharmacology|November 1, 1978
Contrasting subcellular responses to monohydroxytamoxifen and oestradiol benzoate in the immature rat uterus [proceedings]C J Dix, V C Jordan
Biochemical Pharmacology|January 15, 1983
Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapyR R Bain, V C Jordan
Journal of Mammary Gland Biology and Neoplasia|March 8, 2000
The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogensD A Tonetti, V C Jordan
Oncology (Williston Park, N.Y.)|February 1, 1997
Risks and benefits of tamoxifen therapyV J Assikis, V C Jordan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Clinical potential of new antiestrogensW J Gradishar, V C Jordan
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1996
Tamoxifen and endometrial cancer: from experiment to patientV J Assikis, V C Jordan
Cancer Letters|May 25, 1995
Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogueW H Catherino, V C Jordan
Life Sciences|January 1, 1988
Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the ratP M Ravdin, V C Jordan
British Journal of Clinical Pharmacology|April 1, 1979
Control of experimental breast cancer by antioestrogenic therapies [proceedings]C J Dix, V C Jordan
Gynecologic Oncology|May 1, 1992
Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancerD M Wolf, V C Jordan
Pageof 37